Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PharmaNutra SpAMIL:PHN -1.89%88 EV-to-EBITDA is 22.00 as of Aug. 03, 2026, which is 3% above its 10-year median of 21.38. GuruFocus rates MIL:PHN with a GF Score™ of 88/100 and a GF Value™ of €72.43 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 746 Drug Manufacturers companies, PharmaNutra SpA ranks worse than 71.05% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PharmaNutra SpA's enterprise value is €786.6 Mil.
PharmaNutra SpA's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €35.8 Mil. Therefore, PharmaNutra SpA's EV-to-EBITDA for today is 22.00.
The historical rank and industry rank for PharmaNutra SpA's EV-to-EBITDA or its related term are showing as below:
MIL:PHN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 11.98 Med: 21.38 Max: 81.56
Current: 21.99
During the past 11 years, the highest EV-to-EBITDA of PharmaNutra SpA was 81.56. The lowest was 11.98. And the median was 21.38.
MIL:PHN's EV-to-EBITDA is ranked worse than 71.05% of 746
companies
in the Drug Manufacturers industry
Industry Median: 13.015
vs MIL:PHN: 21.99
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PharmaNutra SpA's PE Ratio (TTM) for today is calculated as:
PharmaNutra SpA's share price for today is €83.20.
PharmaNutra SpA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.190.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for PharmaNutra SpA's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:PHN vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PharmaNutra SpA's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaNutra SpA EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PharmaNutra SpA's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PharmaNutra SpA's EV-to-EBITDA falls into.
PharmaNutra SpA's current Enterprise Value is €786.6 Mil.
PharmaNutra SpA's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €35.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmaNutra SpA (MIL:PHN) has a EV-to-EBITDA of 22.00 as of Aug. 03, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PharmaNutra SpA. This is near median its historical median of 21.38. Over the past decade, PharmaNutra SpA's EV-to-EBITDA has ranged from 11.98 to 81.56. According to the industry distribution chart, PharmaNutra SpA ranks #530 out of 746 companies in the Drug Manufacturers industry, placing it in the top 71%.
Is PharmaNutra SpA's EV-to-EBITDA too high?
PharmaNutra SpA's current EV-to-EBITDA of 22.00 is near median its 10-year median of 21.38. Over the past 10 years, this metric has ranged from a low of 11.98 to a high of 81.56. The Drug Manufacturers industry median EV-to-EBITDA is 13.02. PharmaNutra SpA's value of 22.00 is 69% above this industry median. Based on the distribution chart, PharmaNutra SpA ranks #530 out of 746 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, PharmaNutra SpA has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PharmaNutra SpA's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PharmaNutra SpA ranks #530 out of 746 companies for EV-to-EBITDA. This places PharmaNutra SpA in the lower half of its industry. The industry median EV-to-EBITDA is 13.02. PharmaNutra SpA's value of 22.00 is 69% above this benchmark. Historically, PharmaNutra SpA's own EV-to-EBITDA has ranged from 11.98 to 81.56 over the past decade. While the company's 10-year median is 21.38 vs. the industry median of 13.02, PharmaNutra SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.02, based on 746 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmaNutra SpA's current EV-to-EBITDA of 22.00 is 69% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PharmaNutra SpA. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaNutra SpA's current EV-to-EBITDA is 22.00, which is near median its own 10-year median of 21.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaNutra SpA stock overvalued right now?
Based on GuruFocus' analysis, PharmaNutra SpA (MIL:PHN) is currently considered Modestly Overvalued. The stock's GF Value™ is €72.43, compared to a current price of €83.20 — trading 14.9% above its estimated fair value. The current EV-to-EBITDA is 22.00, which is near median its 10-year median of 21.38 and 69% above the Drug Manufacturers industry median of 13.02. PharmaNutra SpA's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For PharmaNutra SpA (MIL:PHN), the current EV-to-EBITDA is 22.00 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PharmaNutra SpA (MIL:PHN) Overvalued in 2026?
Based on GuruFocus' analysis, PharmaNutra SpA stock appears to be overvalued.
The current stock price of €83.20 is trading 14.9% above its estimated GF Value™ of €72.43.
GuruFocus considers PharmaNutra SpA to be Modestly Overvalued.
Key valuation signals for MIL:PHN:
EV-to-EBITDA: 22.00 (near median its 10-year median of 21.38)
GF Value™: €72.43 vs. price of €83.20 (14.9% above fair value)
Industry Position: 69% above the Drug Manufacturers median (#530 of 746)
No single metric tells the full story. See the MIL:PHN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PharmaNutra SpA is a pharmaceutical company. The company is engaged in the research, design, development, and marketing of nutraceutical supplements and medical devices. The products of the company include SiderAL Folic, UltraMag, Cetilar, and others. The company operates in Europe, the Middle East, South America, the Far East, and other regions.
88GF Score
Get the complete analysis for MIL:PHN
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:PHN has been successfully added to your 
